Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
Be 'active' in the market while NOT being tied to your desk.
...
Health Technology » Medical Specialties
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| TMO | Thermo Fisher Scientific, Inc. | -4.95% | 482.68 | 1.0% | $793.96m | |
| DHR | Danaher Corp. | -5.20% | 221.81 | 0.7% | $564.07m | |
| ABT | Abbott Laboratories | -0.41% | 114.26 | 0.8% | $537.76m | |
| ISRG | Intuitive Surgical, Inc. | -1.42% | 758.73 | 2.3% | $504.83m | |
| MDT | Medtronic Plc | -4.52% | 111.47 | 0.6% | $426.46m | |
| BSX | Boston Scientific Corp. | -2.18% | 35.84 | 1.0% | $359.73m | |
| DXCM | DexCom, Inc. | -3.26% | 349.64 | 7.8% | $327.01m | |
| BDX | Becton, Dickinson & Co. | -2.89% | 250.88 | 1.0% | $301.73m | |
| SYK | Stryker Corp. | -3.12% | 230.57 | 1.3% | $238.49m | |
| QDEL | Quidel Corp. | -0.87% | 224.21 | 7.7% | $229.12m | |
| ALGN | Align Technology, Inc. | -4.76% | 509.64 | 6.4% | $228.49m | |
| EW | Edwards Lifesciences Corp. | -1.87% | 84.92 | 0.4% | $201.32m | |
| PEN | Penumbra, Inc. | 2.03% | 271.00 | 8.3% | $197.41m | |
| A | Agilent Technologies, Inc. | -4.17% | 118.75 | 1.6% | $193.08m | |
| BAX | Baxter International, Inc. | -3.56% | 77.93 | 1.8% | $180.96m |
Company Profile
PAVmed, Inc. is a medical device company, which develops and commercializes a pipeline of medical products. Its product portfolio includes DisappEAR, PORTIO, Caldus, Carpx, NextCath, and NextFlo. The firm conducts its operations in four divisions: GI Health, Minimally Invasive Interventions, Infusion Therapy and Emerging Innovations. The GI Health division consists of Edouard Esophageal DNA Test, EsoCheck Esophageal Cell Collection Device, and EsoCure Esophageal Ablation Device with Caldus Technology. The Minimally Invasive Interventions division consists of CarpX, which is a patented, single-use disposable, minimally invasive device designed to treat carpal tunnel syndrome. The Infusion Therapy division consists of PortIO, which is a novel, patented, implantable, intraosseous vascular medical device; and NextFlo, which is designed to deliver gravity-driven infusions independent of the height of the IV bag. The Emerging Innovations division refers to a diversified and expanding portfolio of innovative products designed to address unmet clinical needs across a broad range of clinical conditions. The company was founded on June 26, 2014 and is headquartered in New York, NY.